Green spectrofluorimetric determination of Ibrexafungerp using NBD-Cl derivatization [PDF]
Scientific ReportsIbrexafungerp (IBX) is the first approved triterpenoid antifungal indicated for the treatment of vulvovaginal candidiasis, particularly in cases resistant to azole and echinocandin therapies.
Omkulthom Al kamaly, Mustafa Sayedahmed
doaj +3 more sources
EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates
Journal of Fungi, 2022 Ibrexafungerp is a novel triterpenoid antifungal that inhibits glucan synthase and thus fungal cell wall synthesis. We examined the in vitro activity against contemporary clinical yeast, investigated inter-laboratory and intra-laboratory variability ...
Karin M. Jørgensen +3 more
doaj +5 more sources
Multicenter surveillance of antifungal susceptibility of clinical Aspergillus isolates to conventional and novel antifungal agents in Taiwan, 2021–2023 [PDF]
Microbiology SpectrumPeriodic surveillance of antifungal susceptibility among Aspergillus isolates is essential to guide effective treatment. This multicenter study analyzed 550 clinical Aspergillus isolates collected in Taiwan from 2021 to 2023, primarily from the ...
Ming-I Hsieh +4 more
doaj +2 more sources
Repurposing therapy of ibrexafungerp vulvovaginal candidiasis drugs as cancer therapeutics [PDF]
Frontiers in PharmacologyTedi Rustandi +8 more
doaj +4 more sources
Candida auris: a review of global epidemiology, multidrug resistance, and infection control in healthcare-associated outbreaks [PDF]
Frontiers in Cellular and Infection MicrobiologyCandida auris, designated a critical-priority fungal pathogen by the World Health Organization, poses a growing threat to healthcare systems worldwide. Analysis of 80 peer-reviewed studies reveals five principal findings: (1) C.
Xuewei Du, Li Li
doaj +2 more sources
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis [PDF]
Infection and Drug ResistanceAnna Zubovskaia, Jose A Vazquez Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta University, Augusta, GA, USACorrespondence: Jose A Vazquez, Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta ...
Zubovskaia A, Vazquez JA
doaj +2 more sources
Advances in vulvovaginal candidiasis research: a comprehensive review from epidemiology, diagnosis, treatment to resistance mechanisms [PDF]
Frontiers in MicrobiologyVulvovaginal candidiasis (VVC), predominantly caused by Candida albicans, is one of the most common vaginal infections in women of reproductive age. Its clinical management has become increasingly complex due to the rising prevalence of non-albicans ...
Weipei Zhu, Liangsheng Guo
doaj +2 more sources
Tn-seq screens in Candida glabrata treated with echinocandins and ibrexafungerp reveal pathways of antifungal resistance and cross-resistance [PDF]
mSphereCandida glabrata (also known as Nakaseomyces glabratus) is the second most common cause of candidiasis, next to Candida albicans, and is rising in prevalence due to intrinsic and acquired mechanisms of antifungal resistance.
Timothy J. Nickels, Kyle W. Cunningham
doaj +2 more sources
Ibrexafungerp: A narrative overview
Current Research in Microbial SciencesIbrexafungerp (IBX) is a new antifungal drug that recently entered the antifungal landscape. It disrupts fungal cell wall synthesis by non-competitive inhibition of the β-(1,3)-D-glucan (BDG) synthase enzyme.
L'Emir Wassim El Ayoubi +3 more
doaj +3 more sources
A review of the fernane-type triterpenoids as anti-fungal drugs [PDF]
Frontiers in PharmacologyHuman fungal pathogens could cause a broad plethora of infections in both the immunocompetent and immunocompromised host. Fungal infections have become important causes of morbidity and mortality in recent years, the current arsenal of anti-fungal ...
Chun-Yue Liu +6 more
doaj +2 more sources